ESR1 and prostate carcinoma: This study highlights the potential of SSA as a therapeutic agent for prostate cancer by identifying its key molecular targets (BCL2, ESR1, HIF1A, and STAT3) and validating its anti-proliferative and pro-apoptotic effects in PC3 cells.